- JP-listed companies
- SAPPORO CLINICAL LABORATORY INC.
- Income statement
SAPPORO CLINICAL LABORATORY INC.JP:9776
Market cap
¥8.3B
P/E ratio
12.2x
| 2012/03 | 2013/03 | 2014/03 | 2015/03 | 2016/03 | 2017/03 | 2018/03 | 2019/03 | 2020/03 | 2021/03 | 2022/03 | 2023/03 | 2024/03 | 2025/03 | |
| Revenue | 15,537 | 15,814 | 16,550 | 17,166 | 17,528 | 17,055 | 17,460 | 17,066 | 17,659 | 17,502 | 19,109 | 20,127 | 19,682 | 20,131 |
| Revenue growth (%) | - | |||||||||||||
| Cost of revenue | - | - | - | 12,018 | 12,266 | 11,966 | 12,086 | 11,867 | 12,139 | 11,768 | 12,788 | 13,830 | 13,787 | 13,990 |
| Gross profit | - | - | - | 5,149 | 5,262 | 5,089 | 5,374 | 5,199 | 5,520 | 5,735 | 6,322 | 6,298 | 5,895 | 6,141 |
| Gross margin (%) | - | - | - | |||||||||||
| Operating margin (%) | - | - | - | |||||||||||
| Operating income | - | - | - | 870 | 974 | 772 | 1,017 | 815 | 945 | 1,142 | 1,537 | 1,008 | 534 | 706 |
| Operating expenses | - | - | - | 4,279 | 4,288 | 4,318 | 4,357 | 4,383 | 4,575 | 4,593 | 4,784 | 5,290 | 5,361 | 5,435 |
| Income before tax | 792 | 759 | 933 | 897 | 1,000 | 804 | 1,053 | 813 | 983 | 1,188 | 1,605 | 1,159 | 514 | 708 |
| Pretax margin (%) | 5.1 | 4.8 | 5.6 | 5.2 | 5.7 | 4.7 | 6 | 4.8 | 5.6 | 6.8 | 8.4 | 5.8 | 2.6 | 3.5 |
| Provision for income taxes | - | - | - | 322 | 359 | 232 | 367 | 295 | 317 | 382 | 456 | 319 | 235 | 242 |
| Effective tax rate (%) | - | - | - | |||||||||||
| Net income | 382 | 441 | 492 | 574 | 591 | 514 | 685 | 523 | 528 | 791 | 1,024 | 471 | 460 | 464 |
| Net income margin (%) | ||||||||||||||
| Earnings per share | 104.59 | 115.07 | 124.12 | 150.97 | 169.72 | 147.69 | 197.03 | 152.42 | 154.3 | 231.85 | 306.16 | 170.53 | 114.14 | 148.35 |
| Diluted EPS | 104.59 | 115.07 | 124.12 | 150.97 | 169.72 | 147.69 | 197.03 | 152.42 | 154.3 | 231.85 | 306.16 | 170.53 | 114.14 | 148.35 |
| Dividend payout ratio (%) | ||||||||||||||
| Dividend per share | 11 | 11 | 11 | 12 | 11 | 10 | 11 | 10 | 10 | 23 | 23 | 23 | 23 | 23 |
| EBITDA | - | - | - | |||||||||||
| EBITDA margin (%) | - | - | - |